BridgeBio Pharma, Inc. (BBIO) Stock: Price, Forecast & Analyst Target
BridgeBio Pharma, Inc. (BBIO) — MoonshotScore 20/100 (Weak band), calculated Nov 18, 2026. Price $78.01 (+1.58%), as of the Nov 18, 2026 trading session; market cap $15.2B.
Educational signal · not a buy or sell recommendation · How to read this
BridgeBio Pharma, Inc. · BBIO · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: BridgeBio Pharma is a genetic-disease pharmaceutical developer whose economics now combine product sales with licensing, services and royalties, while research programs span small molecules and gene therapy. The case depends on whether product-led gross profit can overtake a cost base that still produces operating losses and heavy cash use before financing pressure intensifies.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · BridgeBio Pharma (BBIO)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Durable growth, but a strained balance sheet and a full valuation. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Average; Financial Safety: Strained; Valuation: Full; Growth Durability: Growing; Momentum: Rising.
- EPS beat 2 of the last 8 reports
- Altman Z -0.01 · Piotroski F 2
Holding back: balance-sheet strain
Helping: durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 21 | Weak | |
| 20 | Weak | |
| 21 | Weak | |
| 21 | Weak | |
| 20 | Weak | |
| 20 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $78.01 | |
| Change on the day | +1.58% | |
| 52-week range | $62.50–$93.42 | |
| Market capitalisation | $15.2B | — |
| Price / earnings (trailing) | 355.73 | |
| Shares traded on the day | 3.55M | |
| Beta (volatility vs the S&P 500) | 0.97 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for BridgeBio Pharma (BBIO): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company more favourably than the MoonshotScore does: Dalio-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is BridgeBio Pharma (BBIO), and what does it report?
Short answer · as of
BridgeBio identifies and advances therapies for genetic conditions, using disease-focused development programs alongside strategic licensing and collaboration agreements.
Research dated 2026-09-13.
Its accounts now reflect a hybrid pharmaceutical business: product sales form the largest revenue stream, license and service income remains meaningful, and royalties contribute less. Revenue therefore increasingly measures commercial medicine sales alongside partner economics, rather than clinical progress alone.
What do the latest results show for BridgeBio Pharma (BBIO)?
Research dated 2026-09-13.
Revenue and gross profit have risen through successive periods, and the latest earnings release again cleared the revenue expectation. Operating and net results nevertheless remained negative, while the per-share loss was worse than expected.
Product sales are the dominant reported stream, making commercial activity the clearest mechanism behind the higher revenue base. Research spending and selling, general and administrative costs remain large and recently increased, preventing gross profit from translating into operating profit.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $121M | -$183M | -$0.95 (diluted) |
| Q4 FY2025 | $154M | -$193M | -$1.00 (diluted) |
| Q1 FY2026 | $195M | -$164M | -$0.84 (diluted) |
| Q2 FY2026 | $244M | -$152M | -$0.78 (diluted) |
What are the financial strengths and risks for BridgeBio Pharma (BBIO)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13.
BridgeBio retains high gross margins and current liquidity ratios above parity, which support a research-heavy operating model. Those strengths are constrained by debt exceeding cash and investments, recurring negative operating cash flow, and weak distress and quality screens.
The computed cash runway is short relative to the breadth of the development portfolio. If product growth fails to absorb research and commercial spending, BridgeBio may need additional financing while already carrying substantial debt, creating dilution or refinancing risk.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -0.01 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
What should you watch next at BridgeBio Pharma (BBIO)?
Short answer · as of
Current published price targets run low $87.00 · high $156.00 · consensus $110.18 · median $107.00 against a quoted price of $78.01 (as of Nov 18, 2026).
Research dated 2026-09-13.
The scheduled earnings release matters most for whether product-led revenue growth begins to narrow the operating loss. Published expectations call for higher revenue and a smaller per-share loss, while recent history shows that revenue can exceed expectations without comparable earnings improvement.
Watch cash consumed by operations, the cash balance, research spending and the trajectory of selling, general and administrative costs. Recent filings include material agreements and an unregistered equity issuance, making future financing terms relevant to dilution and balance-sheet risk.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does BridgeBio Pharma compare with its peers?
Short answer
BridgeBio Pharma's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
BridgeBio sits between a development-only biotechnology company and an established profitable pharmaceutical producer. It already records meaningful product revenue and very high gross margins, yet it continues to fund a broad genetic-disease pipeline while operating expenses exceed gross profit.
That combination makes commercial scaling and financing inseparable. Compared with development-only businesses, BridgeBio has a recurring product-sales engine; compared with mature pharmaceutical companies, it retains persistent losses, heavy cash use, a short computed runway and debt above liquidity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $68.29 Nov 18, 2026 | $16.7B | 98 5-pillar Nov 18, 2026 | |
| $577.34 Nov 18, 2026 | $24.6B | 97 5-pillar Nov 18, 2026 | |
| $270.33 Nov 18, 2026 | $17.7B | 96 5-pillar Nov 18, 2026 | |
| $315.34 Nov 18, 2026 | $9.34B | 96 5-pillar Nov 18, 2026 | |
| $162.86 Nov 18, 2026 | $16.5B | 95 5-pillar Nov 18, 2026 | |
| $95.80 Nov 18, 2026 | $10.9B | 95 5-pillar Nov 18, 2026 | |
| $72.75 Nov 18, 2026 | $11.4B | 92 5-pillar Nov 18, 2026 | |
| $117.80 Nov 18, 2026 | $24.0B | 91 5-pillar Nov 18, 2026 | |
| $66.12 Nov 18, 2026 | $9.99B | 90 5-pillar Nov 18, 2026 | |
| $127.16 Nov 18, 2026 | $8.30B | 88 5-pillar Nov 18, 2026 | |
| $149.40 Nov 18, 2026 | $20.0B | 72 5-pillar Nov 18, 2026 | |
| $247.77 Nov 18, 2026 | $15.9B | 40 5-pillar Nov 18, 2026 | |
| BridgeBio Pharma (BBIO) — this page | $78.01 | $15.2B | 20 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $87.00 – $156.00
- Consensus target
- $110.18
- Median target
- $107.00
Consensus record · Captured .
Measured against a quoted price of $78.01 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 30, 2026
- Transactions
- 88
- Identified insiders
- 15
- Purchases
- 0
- Sales
- 34
- Other transactions
- 54
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held BBIO in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Viking Global | Andreas Halvorsen | Q3 2026 | 1.97% | $644.33M | Trimmed −1.6% shares |
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.20% | $45.77M | Added +55.2% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about BridgeBio Pharma (BBIO)?
Common Questions About BBIO (Healthcare)
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does BridgeBio sell beyond development rights?
Product sales are its largest revenue category, with license and service revenue adding a meaningful stream and royalties contributing less. Reported revenue therefore increasingly reflects commercial medicine sales rather than partner transactions alone.
Why is BridgeBio still losing money as product revenue rises?
Gross profit has expanded, but research spending and selling, general and administrative costs still exceed what the commercial base can support. Operating cash flow also remains negative, showing that revenue growth has not yet made the business self-funding.
What is BridgeBio's transthyretin stabilizer?
It is a small-molecule program designed to stabilize transthyretin for amyloidosis cardiomyopathy. The program exemplifies BridgeBio's approach of targeting the molecular cause of a genetic disease within a broader portfolio.
Can product sales fund BridgeBio's genetic-disease pipeline yet?
Current operations still consume cash despite expanding product revenue, so internal funding is not yet sufficient. Cash provides a buffer, but debt exceeds liquidity and the computed runway remains short.
What is the BBIO stock price today?
The last price recorded for BridgeBio Pharma, Inc. (BBIO), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the BBIO price target?
The analyst consensus price target for BridgeBio Pharma, Inc. (BBIO), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 23 figures on this page — 1 from SEC filings and earnings calls, 18 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com